ArticleESMO open2019
Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST.
Article in ESMO open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- Magnetic resonance imaging signal variation for the effective quantitative evaluation of treatment response to neoadjuvant immunotherapy of osteosarcoma: a comparative study with Response Evaluation Criteria in Solid Tumors version 1.1.Quantitative imaging in medicine and surgery · 2026Article
- Current Position of Nuclear Medicine Imaging in Primary Bone Tumors.Diagnostics (Basel, Switzerland) · 2025Review
- Efficacy assessment in phase I clinical trials: endpoints and challenges.Annals of oncology : official journal of the European Society for Medical Oncology · 2025Review
- PET Criteria by Cancer Type from Imaging Interpretation to Treatment Response Assessment: Beyond FDG PET Score.Life (Basel, Switzerland) · 2023Review
- Current and future targeted alpha particle therapies for osteosarcoma: Radium-223, actinium-225, and thorium-227.Frontiers in medicine · 2022Review
- Review
- Molecular Biology of Osteosarcoma.Cancers · 2020Review
- Preclinical PERCIST and 25% of SUVJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Article
- 223-Radium for metastatic osteosarcoma: combination therapy with other agents and external beam radiotherapy.ESMO open · 2020Article
- Radiopharmaceuticals for Treatment of Osteosarcoma.Advances in experimental medicine and biology · 2020Review
- Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Comprehensive molecular imaging of malignant transformation of giant cell tumour of bone reveals diverse disease biology.BMJ case reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
purposeThe development of osteosarcoma therapeutics has been challenging, in part because of the lack of appropriate criteria to evaluate responses. We developed a novel criteria in a clinical trial of radium-223 dichloride ( EXPERIMENTAL
designPatients received one to six cycles of
resultsOf the 18 patients, 17 had bone lesions visible in at least one of the imaging studies. In four of seven patients with multiple skeletal lesions (>5), FDG PET and NaF PET studies could be compared. The skeletal tumour locations varied in our patient population: cranium=2, extremities=7, pelvis=10, spine=12 and thorax=9. The
conclusionsOur results indicate that Na
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.